Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBioXcel Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$1.05 | -$0.38 | -$0.67 |
| Q2 2024 | 2 | -$1.11 | -$0.41 | -$0.71 |
| Q3 2024 | 1 | -$0.79 | -$0.29 | -$0.51 |
| Q4 2024 | 1 | -$0.56 | -$0.35 | -$0.46 |
| Q1 2025 | 1 | -$0.70 | -$0.26 | -$0.45 |
| Q2 2025 | 1 | -$0.70 | -$0.26 | -$0.45 |
| Q3 2025 | 1 | -$0.61 | -$0.22 | -$0.39 |
| Q4 2025 | 1 | -$0.44 | -$0.16 | -$0.28 |
BioXcel Therapeutics, Inc. Earnings Date And Information
BioXcel Therapeutics, Inc. last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.21 earnings per share for the quarter, topping analysts' consensus estimates of $-0.76 by $0.55. The company had revenue of 214,000 for the quarter and had revenue of 1.38 M for the year. BioXcel Therapeutics, Inc. has generated $-6 earnings per share over the last year ($-6.15 diluted earnings per share) and currently has a price-to-earnings ratio of -0.24. BioXcel Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based on prior year's report dates.
BioXcel Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.32 | $1.33 M | $214,000 | ||
| 08/06/2024 | Q2 2024 | -$0.76 | -$0.21 | 0.55 | $762,500 | $1.10 M |
| 05/09/2024 | Q1 2024 | -$0.68 | -$0.87 | -0.19 | $582,000 | |
| 03/22/2024 | Q4 2023 | -$0.76 | $376,000 | |||
| 09/29/2023 | Q3 2023 | -$1.72 | $626,000 | $341,000 | ||
| 08/14/2023 | Q2 2023 | -$1.72 | -$1.83 | -0.11 | $453,889 | $457,000 |
| 05/08/2023 | Q1 2023 | -$1.78 | $206,000 | |||
| 05/01/2023 | Q4 2022 | -$2.07 | $238,000 | |||
| 11/14/2022 | Q3 2022 | -$1.59 | $1.00 M | $137,000 | ||
| 08/11/2022 | Q2 2022 | -$1.40 | $0 | |||
| 05/09/2022 | Q1 2022 | -$1.21 | -$1.12 | 0.09 | $0 | |
| 03/10/2022 | Q4 2021 | -$0.93 | $0 | |||
| 11/10/2021 | Q3 2021 | -$1.08 | -$0.96 | 0.12 | $0 | |
| 08/10/2021 | Q2 2021 | -$1.03 | -$1.11 | -0.08 | $0 | |
| 05/10/2021 | Q1 2021 | -$0.89 | -$1.08 | -0.19 | $0 | |
| 03/12/2021 | Q4 2020 | -$0.87 | $0 | |||
| 11/12/2020 | Q3 2020 | -$0.80 | -$1.07 | -0.27 | $0 | |
| 08/14/2020 | Q2 2020 | -$0.74 | -$1.06 | -0.32 | $0 | |
| 05/12/2020 | Q1 2020 | -$0.55 | -$0.79 | -0.24 | $0 | |
| 03/09/2020 | Q4 2019 | -$0.67 | -$0.46 | 0.21 | $0 |
BioXcel Therapeutics, Inc. Earnings: FAQ's
When is BioXcel Therapeutics, Inc.'s earnings date?
BioXcel Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's report dates.
Did BioXcel Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, BioXcel Therapeutics, Inc. (:BTAI) reported $-0.21 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.76 by $0.55.
How can I listen to BioXcel Therapeutics, Inc.'s earnings conference
call?
The conference call for BioXcel Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read BioXcel Therapeutics, Inc.'s conference call transcript?
The conference call transcript for BioXcel Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does BioXcel Therapeutics, Inc. generate each year?
BioXcel Therapeutics, Inc. (:BTAI) has a recorded annual revenue of $1.38 M.
How much profit does BioXcel Therapeutics, Inc. generate each year?
BioXcel Therapeutics, Inc. (:BTAI) has a recorded net income of $1.38 M. BioXcel Therapeutics, Inc. has generated $-6.15 earnings per share over the last four quarters.
What is BioXcel Therapeutics, Inc.'s price-to-earnings ratio?
BioXcel Therapeutics, Inc. (:BTAI) has a price-to-earnings ratio of -0.24 and price/earnings-to-growth ratio is -0.01.